The Use of Aspirin in Ischemic Heart Disease

Jane F. Desforges, John E. Willard, Richard A. Lange, L. David Hillis

Research output: Contribution to journalReview article

142 Scopus citations

Abstract

WITHIN a decade of the isolation of salicylate in 1892, aspirin was introduced as an analgesic and antipyretic agent. In 1971, Vane described its inhibition of prostaglandin synthesis from arachidonate in homogenates of guinea pig lung,1 and Smith and Willis demonstrated that aspirin blocks the production of prostaglandin in human platelets.2 During the past decade, it has been shown that platelet aggregation and the formation of thrombi are pathophysiologically important in syndromes of ischemic heart disease. As a result, aspirin is widely used in patients with ischemic heart disease, and its use has recently been advocated in subjects without clinically…

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalNew England Journal of Medicine
Volume327
Issue number3
DOIs
StatePublished - Jul 16 1992

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The Use of Aspirin in Ischemic Heart Disease'. Together they form a unique fingerprint.

  • Cite this

    Desforges, J. F., Willard, J. E., Lange, R. A., & Hillis, L. D. (1992). The Use of Aspirin in Ischemic Heart Disease. New England Journal of Medicine, 327(3), 175-181. https://doi.org/10.1056/NEJM199207163270308